Co-Authors
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and BORJE S ANDERSSON.
Connection Strength
0.463
-
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7.
Score: 0.055
-
Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2016 07; 22(7):1218-1226.
Score: 0.034
-
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53.
Score: 0.033
-
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994 Sep; 12(9):1923-30.
Score: 0.031
-
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant. 1994 Jul; 14(1):57-61.
Score: 0.030
-
Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). Hum Gene Ther. 1993 Dec; 4(6):821-34.
Score: 0.029
-
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 1993 Aug 01; 53(15):3603-10.
Score: 0.028
-
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92.
Score: 0.025
-
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S261-5.
Score: 0.021
-
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer. 1988 Aug 15; 62(4):672-6.
Score: 0.020
-
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007 Jul 15; 110(2):340-4.
Score: 0.019
-
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Aug 15; 108(4):1421-3.
Score: 0.017
-
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood. 1995 Jun 01; 85(11):3257-63.
Score: 0.016
-
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5.
Score: 0.012
-
Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21.
Score: 0.012
-
Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia. 1997 Oct; 11(10):1621-30.
Score: 0.010
-
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6.
Score: 0.009
-
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996 Mar; 100(3):299-307.
Score: 0.009
-
Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. Clin Infect Dis. 1993 Dec; 17(6):1022-31.
Score: 0.007
-
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med. 1993 Sep 09; 329(11):757-61.
Score: 0.007
-
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993 Jun; 11(6):1055-61.
Score: 0.007
-
Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine. Hum Gene Ther. 1993 Feb; 4(1):71-85.
Score: 0.007
-
Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989 Aug; 7(8):1071-80.
Score: 0.005
-
Detection of leukemic clone maturation in vivo by premature chromosome condensation. Blood. 1988 Dec; 72(6):1950-60.
Score: 0.005
-
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer. 1988 Aug 15; 62(4):677-82.
Score: 0.005
-
Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. Leukemia. 1987 Jan; 1(1):52-7.
Score: 0.005
-
Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104.
Score: 0.004